Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Vitro Diagnostics (VODG) had Return on Tangible Equity of 7.70% for the most recently reported fiscal quarter, ending 2026-04-30.
| Income Statement Financials | |
$0.45M |
|
$-1.59M |
|
$0.10M |
|
$0.34M |
|
$1.62M |
|
$-1.17M |
|
$-0.38M |
|
$-1.55M |
|
$-1.55M |
|
$-1.55M |
|
$-1.55M |
|
$-1.55M |
|
$-1.55M |
|
$-1.17M |
|
$-0.67M |
|
4.52M |
|
4.52M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$0.36M |
|
$0.06M |
|
$4.01M |
|
$4.37M |
|
$16.63M |
|
$3.29M |
|
$4.28M |
|
$20.91M |
|
$-16.53M |
|
$-20.18M |
|
$-16.53M |
|
4.52M |
|
| Cash Flow Statement Financials | |
$-1.54M |
|
$-0.04M |
|
$1.10M |
|
$0.60M |
|
$0.12M |
|
$-0.48M |
|
$0.53M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-0.25 |
|
-0.61 |
|
76.74% |
|
-262.62% |
|
-262.62% |
|
-- |
|
-348.03% |
|
-356.97% |
|
$-1.57M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
0.75 |
|
7.17 |
|
12.55 |
|
9.39% |
|
|
Return on Tangible Equity |
7.70% |
-35.50% |
|
11.73% |
|
$-3.66 |
|
$-0.35 |
|
$-0.34 |
|